Heng Mei

7.4k total citations · 1 hit paper
169 papers, 2.9k citations indexed

About

Heng Mei is a scholar working on Oncology, Hematology and Immunology. According to data from OpenAlex, Heng Mei has authored 169 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Oncology, 43 papers in Hematology and 39 papers in Immunology. Recurrent topics in Heng Mei's work include CAR-T cell therapy research (66 papers), Platelet Disorders and Treatments (18 papers) and Immune Cell Function and Interaction (14 papers). Heng Mei is often cited by papers focused on CAR-T cell therapy research (66 papers), Platelet Disorders and Treatments (18 papers) and Immune Cell Function and Interaction (14 papers). Heng Mei collaborates with scholars based in China, United States and United Kingdom. Heng Mei's co-authors include Yu Hu, Danying Liao, Peter J. Newman, Panida Lertkiatmongkol, Lu Tang, Chenggong Li, Huiwen Jiang, Huafang Wang, Jun Deng and Zhinan Yin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Heng Mei

151 papers receiving 2.8k citations

Hit Papers

Endothelial functions of ... 2016 2026 2019 2022 2016 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31)
    2016 410 citations Danying Liao, Heng Mei et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Heng Mei 1.1k 807 557 471 435 169 2.9k
Tobias Herold 448 0.4× 926 1.1× 308 0.6× 587 1.2× 859 2.0× 121 2.9k
Qiubai Li 559 0.5× 1.7k 2.2× 405 0.7× 335 0.7× 377 0.9× 99 3.3k
Albert D. Donnenberg 1.6k 1.5× 1.4k 1.7× 1.4k 2.5× 237 0.5× 474 1.1× 138 5.3k
Stefan Gattenlöhner 1.0k 1.0× 1.2k 1.5× 723 1.3× 137 0.3× 260 0.6× 147 4.4k
Mengtao Li 793 0.8× 858 1.1× 1.4k 2.5× 339 0.7× 379 0.9× 375 5.5k
Aaron P. Rapoport 2.1k 2.0× 1.2k 1.5× 703 1.3× 99 0.2× 1.1k 2.4× 162 3.8k
Lynn Sorbara 1.7k 1.6× 686 0.9× 762 1.4× 184 0.4× 209 0.5× 58 4.0k
Zhichao Fan 310 0.3× 545 0.7× 467 0.8× 352 0.7× 146 0.3× 85 2.0k
Mark B. Headley 1.1k 1.1× 698 0.9× 1.9k 3.4× 170 0.4× 360 0.8× 32 3.7k

Countries citing papers authored by Heng Mei

Since Specialization
Citations

This map shows the geographic impact of Heng Mei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heng Mei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heng Mei more than expected).

Fields of papers citing papers by Heng Mei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heng Mei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heng Mei. The network helps show where Heng Mei may publish in the future.

Co-authorship network of co-authors of Heng Mei

This figure shows the co-authorship network connecting the top 25 collaborators of Heng Mei. A scholar is included among the top collaborators of Heng Mei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heng Mei. Heng Mei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Zhang, Min, Yingying Wu, Lu Zhang, et al.. (2025). Zanubrutinib plus R-CHOP improves the treatment effect of newly diagnosed diffuse large B cell lymphoma with double expression of MYC and BCL-2. Frontiers in Immunology. 16. 1526318–1526318.
5.
Mei, Heng, Qi Cai, Jiajia Zhou, et al.. (2025). hTAS2R38 polymorphisms modulate oral microbiota and influence the prevalence and treatment outcome of halitosis. Microbiome. 13(1). 85–85. 2 indexed citations
6.
7.
Mei, Heng & Anxin Guo. (2024). Toward the response of coastal bridges with updated RC shear key properties under the multi-hazard action of earthquakes and tsunamis. Ocean Engineering. 297. 117048–117048. 4 indexed citations
8.
Mei, Heng & Anxin Guo. (2024). Finite element analysis and simplified envelope curve model for RC shear key under earthquake-tsunami actions. Soil Dynamics and Earthquake Engineering. 183. 108799–108799.
9.
Mei, Heng & Anxin Guo. (2024). Experimental and analytical investigations on backbone curve models for RC shear keys under sequential seismic-tsunamic impacts. Engineering Structures. 305. 117691–117691. 3 indexed citations
10.
Wang, Ying, Qingsong Yin, Hongsheng Zhou, et al.. (2024). Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.. Journal of Clinical Oncology. 42(16_suppl). 6505–6505. 2 indexed citations
11.
Huang, Liang, Heng Mei, Yuhua Li, et al.. (2024). Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China. Journal for ImmunoTherapy of Cancer. 12(5). e008553–e008553. 10 indexed citations
12.
Zhou, Hu, Yongjun Fang, Yunfeng Cheng, et al.. (2024). Clinical and genetic characteristics of 40 patients with nonmuscle myosin heavy chain 9-related disease (MYH9-RD) misdiagnosed as immune thrombocytopenia: a retrospective analysis in China. Journal of Thrombosis and Haemostasis. 23(3). 1043–1051. 1 indexed citations
13.
Mei, Heng, Hu Zhou, Ming Hou, et al.. (2023). Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China. Research and Practice in Thrombosis and Haemostasis. 7(6). 102158–102158. 9 indexed citations
14.
15.
Zhang, Yinqiang, Chenggong Li, Mengyi Du, et al.. (2023). Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer Journal. 13(1). 61–61. 52 indexed citations
16.
Du, Mengyi, et al.. (2023). [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].. PubMed. 44(10). 793–799. 3 indexed citations
17.
Xu, Aoshuang, Jiasi Zhang, Liping Zuo, et al.. (2021). FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m6A-YTHDF2-dependent manner. Molecular Therapy. 30(3). 1104–1118. 50 indexed citations
18.
Tang, Lu, Jianghua Wu, Huiwen Jiang, et al.. (2020). Characterization of Immune Dysfunction and Identification of Prognostic Immune-Related Risk Factors in Acute Myeloid Leukemia. Clinical Cancer Research. 26(7). 1763–1772. 88 indexed citations
19.
Li, Chenggong, Heng Mei, & Yu Hu. (2019). Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy. Briefings in Functional Genomics. 19(3). 175–182. 64 indexed citations
20.
Jiang, Huiwen, Heng Mei, Jian Dong, & Yu Hu. (2017). Abnormal Coagulation Function in CD19-Targeted CAR-T Therapy. Blood. 130. 2607–2607. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tobias Herold Breakdown of academic impact, for papers by Qiubai Li Breakdown of academic impact, for papers by Albert D. Donnenberg Breakdown of academic impact, for papers by Stefan Gattenlöhner Breakdown of academic impact, for papers by Mengtao Li Breakdown of academic impact, for papers by Aaron P. Rapoport Breakdown of academic impact, for papers by Lynn Sorbara Breakdown of academic impact, for papers by Zhichao Fan Breakdown of academic impact, for papers by Mark B. Headley
Rankless by CCL
2026